Agnosia

Summary

Agnosia (MONDO:0005638) is a disease (an umbrella term covering 20 Mondo subtypes). A subtype of perceptual disorders — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Umbrella term: 20 Mondo subtypes

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	agnosia
Mondo ID	MONDO:0005638
EFO	EFO:0007136
MeSH	D000377
DOID	DOID:4090
ICD-10-CM	R48.1
ICD-11	1315065296
NCIT	C84542
SNOMED CT	68345001
UMLS	C0001816
MedGen	174
GARD	0027722
Is cancer (heuristic)	no

Also known as: agnosia · Monomodal visual amnesia · primary visual agnosia · visual amnesia

Disease family

This is a subtype of perceptual disorders. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › perceptual disorders › agnosia

Related subtypes (8): apraxia, vestibular disorder, inherited retinal dystrophy, vision disorder, hearing disorder, auditory perceptual disorders, allesthesia, hallucinogen-persisting perception disorder

Subtypes (20): akinetopsia, alexithymia, amusia, anosognosia, auditory agnosia, autotopagnosia, cortical deafness, finger agnosia, integrative agnosia, mirror agnosia, pain agnosia, phonagnosia, semantic agnosia, simultanagnosia, social emotional agnosia, astereognosia, tactile agnosia, time agnosia, visual agnosia, prosopagnosia

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.